Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32214| Title: | Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. | Austin Authors: | Carneiro, Benedito A;Papadopoulos, Kyriakos P;Strickler, John H;Lassman, Andrew B;Waqar, Saiama N;Chae, Young Kwang;Patel, Jyoti D;Shacham-Shmueli, Einat;Kelly, Karen;Khasraw, Mustafa;Bestvina, Christine M;Merrell, Ryan;Huang, Kevin;Atluri, Harisha;Ansell, Peter;Li, Rachel;Jin, Janet;Anderson, Mark G;Reilly, Edward B;Morrison-Thiele, Gladys;Patel, Kalpesh;Robinson, Randy R;Aristide, Martha R Neagu;Gan, Hui K | Affiliation: | Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA. START San Antonio, San Antonio, Texas, USA. Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA. Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, the Herbert Irving Comprehensive Cancer Center, New York, New York, USA. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA. Department of Oncology, Sheba Medical Center, Ramat Gan, Israel. University of California Davis Comprehensive Cancer Center, Sacramento, California, USA. The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA. The University of Chicago Medicine, Chicago, Illinois, USA. Department of Neurology, NorthShore University Health System, Evanston, Illinois, USA. AbbVie Inc., North Chicago, Illinois, USA. AbbVie Inc., South San Francisco, California, USA. Medical Oncology |
Issue Date: | 2023 | Date: | 2022 | Publication information: | Neuro-oncology advances 2023; 5(1):vdac183 | Abstract: | Serclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer. We investigated Ser-T monotherapy in a phase I, first-in-human, dose-escalation, and dose-expansion study in patients with advanced solid tumors associated with EGFR overexpression. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32214 | DOI: | 10.1093/noajnl/vdac183 | ORCID: | 0000-0002-5468-1126 0000-0001-7386-9928 0000-0003-3249-9849 |
Journal: | Neuro-oncology advances | Start page: | vdac183 | PubMed URL: | 36814898 | ISSN: | 2632-2498 | Type: | Journal Article | Subjects: | EGFR antibody-drug conjugate glioblastoma phase I serclutamab talirine |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.